title: Reduced incidence of intraoperative complications in a multicenter controlled clinical trial of triamcinolone in vitrectomy.
abstract: OBJECTIVE
  To evaluate the benefits and potential complications of using triamcinolone acetonide (TA) in pars plana vitrectomy (PPV).
  
  
  METHODS
  Multicenter, prospective, controlled clinical trial.
  
  
  METHODS
  In total, 774 patients from 8 Japanese hospitals were enrolled, with 391 patients undergoing TA-assisted PPV and 383 control patients undergoing conventional PPV.
  
  
  METHODS
  Intraoperative use of TA to aid visualization of the vitreous.
  
  
  METHODS
  The incidence of intraoperative complications, including retinal breaks, was evaluated. Early postoperative complications, intraocular pressure (IOP), and adverse events occurring within 3 months of the operation were also monitored.
  
  
  RESULTS
  The incidence of both retinal breaks and intraoperative retinal detachment was significantly lower in TA-assisted PPV than in conventional PPV. Retinal breaks were seen in 34 eyes (8.7%) undergoing TA-assisted PPV compared with 54 eyes (14.1%) undergoing conventional PPV (odds ratio [OR], 0.603; 95% confidence interval [CI], 0.381-0.955; P = 0.031). Retinal detachment was seen in only 3 eyes (0.8%) in which TA was used compared with 14 eyes (3.7%) in which TA was not used (OR, 0.204; 95% CI, 0.057-0.727; P = 0.014). In total, 388 eyes in the TA-assisted PPV group (99.2%) and 374 eyes in the conventional PPV group (97.6%) were followed up for 3 months after the operation. Although the mean postoperative IOPs were comparable in both groups, antiglaucoma eye drops were used more frequently by patients in the TA-assisted group than by those in the conventional PPV group (OR, 1.673; 95% CI, 1.126-2.484; P = 0.011). No serious adverse events, such as endophthalmitis or retinal degeneration, were observed in either group.
  
  
  CONCLUSIONS
  Intraoperative use of TA reduced the incidence of retinal breaks and retinal detachments in eyes undergoing PPV. There were no serious adverse events related to the intraoperative use of TA. Although antiglaucoma eye drops were required more frequently after TA-assisted PPV than after conventional PPV, IOP was well-controlled in both groups.
authors.affiliation: Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan.
authors.forename: Keita
authors.initials: K
authors.lastname: Yamakiri
authors.forename: Taiji
authors.initials: T
authors.lastname: Sakamoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Noda
authors.forename: Masaaki
authors.initials: M
authors.lastname: Nakahara
authors.forename: Nobuchika
authors.initials: N
authors.lastname: Ogino
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kubota
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Yokoyama
authors.forename: Mariko
authors.initials: M
authors.lastname: Furukawa
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Sonoda
authors.forename: Tomomi
authors.initials: T
authors.lastname: Yamada
authors.forename: Norihito
authors.initials: N
authors.lastname: Doi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Enaida
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Hata
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishibashi
mesh_terms: D005260:Female; D005466:Fluorocarbons / Q000008:administration & dosage; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure; D007431:Intraoperative Complications; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D011446:Prospective Studies; D012163:Retinal Detachment / Q000453:epidemiology / Q000209:etiology; D012167:Retinal Perforations / Q000453:epidemiology / Q000209:etiology; D012827:Silicone Oils / Q000008:administration & dosage; D016037:Single-Blind Method; D013459:Sulfur Hexafluoride / Q000008:administration & dosage; D014222:Triamcinolone Acetonide / Q000009:adverse effects; D014821:Vitrectomy / Q000379:methods*; D014822:Vitreous Body / Q000473:pathology
chemical_list: D005466:Fluorocarbons; D005938:Glucocorticoids; D012827:Silicone Oils; C042852:perflutren; D014222:Triamcinolone Acetonide; D013459:Sulfur Hexafluoride